Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa
2006

Clarithromycin as an Immunomodulator in Urosepsis

Sample size: 40 publication Evidence: moderate

Author Information

Author(s): Giamarellos-Bourboulis Evangelos J, Antonopoulou Anastasia, Raftogiannis Maria, Koutoukas Pantelis, Tsaganos Thomas, Tziortzioti Vassiliki, Panagou Charalambos, Adamis Theodoros, Giamarellou Helen

Primary Institution: 4th Department of Internal Medicine, University of Athens, Medical School, Greece

Hypothesis

Can clarithromycin improve survival in experimental urosepsis caused by multidrug-resistant Pseudomonas aeruginosa when administered late?

Conclusion

Clarithromycin administered late in experimental urosepsis by multidrug-resistant P. aeruginosa prolonged survival and improved clinical outcomes.

Supporting Evidence

  • Clarithromycin improved survival rates in treated rabbits compared to controls.
  • The combination of clarithromycin and amikacin showed a significant survival advantage.
  • Clarithromycin reduced total oxidant status in treated animals.

Takeaway

Clarithromycin can help sick rabbits live longer when they have a serious infection, even if it's given after the infection starts.

Methodology

40 rabbits were divided into four groups and treated with clarithromycin, amikacin, both, or saline after inducing urosepsis.

Limitations

The study was conducted on rabbits, which may not fully represent human responses.

Participant Demographics

40 white New Zealand male rabbits, mean weight 3.19 kg.

Statistical Information

P-Value

0.049

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2334-6-31

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication